Peles Therapeutics

Monoclonal Antibody Treatment for Peripheral Artery Disease

Health Tech & Life Sciences

Non Active, Aug 2022 ceased to operate

Seed Rehovot Founded 2021

Total raised

—

Last: Undisclosed 2021-07

Stage

Seed

Founded

2021

Headcount

Rehovot

Sector

Health Tech & Life Sciences

About

Peles Therapeutics is developing a humanized monoclonal antibody targeting the receptor for advanced glycation end products. With technology in-licensed from Columbia University, the company aims to address the unmet need of peripheral artery disease in diabetic patients using this novel approach.

Funding history · 1 round · — total

2021-07

Undisclosed Undisclosed

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsMolecules

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

Name	Peles Therapeutics
Slug	peles-therapeutics
Type	Israeli Startup
Founded	2021
HQ city	Rehovot
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object]
Status	inactive
Current stage	Seed
Public stage	Seed
Total raised (USD)	0
Last round	Undisclosed (2021-07)
Israeli Companies Registrar	516395555

Peles Therapeutics

About

Funding history · 1 round · — total

Sectors & technology

Tags